Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Biosciences Raises $25M in Series C Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Predictive Biosciences today said it has completed a Series C financing round, raising $25 million.

Proceeds will be used to complete multi-center clinical trials for Predictive's CertNDx bladder cancer assay and to launch the test through the company's CLIA laboratories, it said in a statement.

CertNDx uses Predictive's Multi-Analyte Diagnostic Readout, or MADR, approach, which combines DNA and protein biomarkers into one assay.

Proceeds will also be used to help fund the commercial and operational growth of OncoDiagnostic Laboratory, including the expansion of ODL's facilities to support its growing national customer base, the company said. Predictive, based in Lexington, Ky., acquired ODL in January for an undisclosed amount.

The Series C round was led by new investor ProQuest Investments. Jay Moorin, general partner with ProQuest has joined Predictive's board, as a result.

Existing investors Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, and New Enterprise Associates also participated in the round.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.